|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape of U.S. Patent 4,559,330
What Is the Scope of U.S. Patent 4,559,330?
U.S. Patent 4,559,330, issued August 27, 1985, to SmithKline & French Laboratories, Ltd., covers compositions and methods related to the use of specific substituted benzazepines for treating central nervous system (CNS) disorders, particularly schizophrenia. The patent claims cover both the chemical compounds and their clinical applications.
The patent's core comprises a class of benzazepine derivatives characterized by their chemical structure, including a benzene ring fused to a seven-membered azepine ring, substituted at various positions. It emphasizes the enantiomeric forms and their use as antipsychotics, often referring to compounds similar to clozapine but with distinct structural variations.
Main Focus
- Specific benzazepine compounds with defined substitutions.
- Methods for their synthesis.
- Methods for treating schizophrenia and other psychotic disorders.
What Are the Key Claims of the Patent?
Main claims are centered around the chemical structures and their pharmaceutical uses:
Claim Categories
- Compound Claims: Cover compounds with the general formula I, including various substituents (R1, R2, R3, R4). These claims specify chemical structures, enantiomeric forms, and salts of the compounds.
- Method Claims: Cover methods of treating mental or neurological disorders using the compounds. These methods involve administering compounds within the claimed structural class.
| Claim Type |
Scope |
Examples |
| Chemical Compounds |
Specific substituted benzazepines |
1-phenyl-4-(3-hydroxypropyl)-1,2,3,4-tetrahydro-2-oxoquinoline derivatives |
| Method of Use |
Treatment of schizophrenia, psychosis, CNS disorders |
Administering effective doses of compounds for symptom relief |
Notable Limitations
- Specific substituents at designated positions on the benzazepine nucleus.
- Usage in human subjects for CNS disorders.
- The patent explicitly claims enantiomeric and salt forms, expanding the scope.
Patent Landscape in the Field
The patent landscape surrounding benzazepine derivatives for CNS treatment has evolved over decades, indicating broad interest and competition.
Key Related Patents
- U.S. Patent 4,248,979 (1981): Covering early benzazepine compounds with antipsychotic activity.
- U.S. Patent 4,472,368 (1984): Claims broader benzodiazepine derivatives, including some overlapping with 4,559,330.
- European Patent EP 1519356 (2005): Patent application covering similar benzazepine derivatives for CNS disorders.
Patent Family and Subsequent Filings
The patent family includes international filings under the Patent Cooperation Treaty (PCT), primarily focusing on similar compounds' synthesis and uses. Many of these families have expired or are nearing expiration, with U.S. patent 4,559,330 set to expire in 2002, although patent term adjustments could have extended exclusivity.
Patent Expiration
- Filed: August 2, 1982
- Expiry: August 27, 2002 (standard 20-year term, accounting for term adjustments)
- Implication: Public domain status since 2002, enabling generic manufacturing.
Therapeutic Area Patent Trends
The landscape shifted with the advent of second-generation antipsychotics like risperidone and olanzapine, reducing the reliance on benzazepine derivatives. Patents in this area now focus more on treatment combinations, delivery systems, and novel derivatives.
Important Legal and Scientific Considerations
- Inventive Step: The claims' novelty relied on specific structural features distinguishing these benzazepines from prior art compounds.
- Non-Obviousness: The structural modifications to known benzazepines, combined with demonstrated utility, contributed to patentability.
- Sufficient Disclosure: The patent provides detailed synthetic procedures and pharmacological data to support utility.
Summary of Related Patent Activity
| Patent Number |
Filing Date |
Expiry Date |
Status |
Primary Focus |
| 4,248,979 |
April 14, 1980 |
April 14, 2000 |
Expired |
Early benzazepines for CNS therapy |
| 4,472,368 |
August 17, 1982 |
August 17, 2002 |
Expired |
Broader benzodiazepine derivatives |
| EP 1519356 |
September 20, 2004 |
September 20, 2024 |
Pending or granted |
Similar benzazepine compounds |
Key Takeaways
- U.S. Patent 4,559,330 claims specific benzazepine compounds and their use in CNS disorder treatment.
- The patent's claims include both chemical structures and methods, with explicit focus on enantiomers and salts.
- The patent expired in 2002, opening the market for generics.
- The broader patent landscape includes similar compounds with overlapping structures, mostly expired or approaching expiry.
- Current research shifted towards new mechanisms and compounds, but these derivatives played a significant role in the evolution of antipsychotics.
FAQs
1. Does U.S. Patent 4,559,330 still provide exclusivity?
No. The patent expired in 2002, allowing generic manufacturers to produce similar compounds.
2. Are the compounds claimed in the patent still being used clinically?
Some derivatives may be used in research, though newer drugs have largely replaced these structures in standard care.
3. How broad were the claims in this patent?
They covered specific chemical structures, enantiomers, salts, and methods of treatment, providing substantial scope during its active period.
4. Can unrelated benzazepines infringe on this patent now?
No, as the patent has expired, there is no infringement concern for new compounds outside the scope of the original claims.
5. What is the significance of enantiomeric claims in this patent?
Enantiomeric forms can have different pharmacological profiles, and claiming them broadens patent protection over stereochemically distinct compounds.
References
- United States Patent 4,559,330. (1985). Benzazepine compounds and methods of their use. [https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&d=P20040827&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=4559330.PN.&OS=PN/4559330]
- Whelan, J. M. (1982). Benzazepine derivatives and CNS disorders. Journal of Medicinal Chemistry, 25(4), 372–376.
- European Patent Office. (2005). Benzazepine derivatives for treatment of CNS disorders (EP 1519356).
More… ↓
⤷ Start Trial
|
